SP Acquires Spain Based i-Dositecno
"i-Dositecno has a well-earned reputation for producing high quality, fill-finish equipment complemented by strong software engineering capabilities and innovative servicing and support," stated SP CEO Brian Larkin. "At SP we are continually focused on bringing value to our customer relationships and i-Dositecno's current portfolio, engineering expertise and broad capabilities in liquid filling particularly for syringes and other cartridges in addition to vials, are a very strategic complement to our Hull and VirTis freeze dryers and PennTech aseptic vial processing lines."
Larkin continued by saying, "As biological drug development and treatment protocols have become more specialized, we expect short-run aseptic liquid filling to continue to drive pharmaceutical growth. With the addition of i-Dositecno to our SP brand, we now join a very select group of manufacturers with the capability to provide full lines. And, while SP has traditionally had a stronger equipment footprint in the United States, i-Dositecno's efforts and success have primarily been within Europe and Asia. These relationships, as well as the addition of a Spain location to our current UK manufacturing within Europe provide significant opportunity to better serve the world-wide market. Key manufacturing, engineering, sales and service personnel from i-Dositecno have joined the SP team to assure continuity in operations and service. Oriol Casoliva, founder and past CEO of i-Dositecno will join SP's Executive Leadership Team and we look forward to benefiting from his vision and depth of knowledge in maximizing i-Dositecno and SP's performance within the aseptic pharmaceutical manufacturing space."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.